Continuous real-time fentanyl sensor platform based on smart hydrogels for application in anesthesia
Award amount
$222,921Program and phase
STTR · Phase IAward year
2019Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- SENTIOMED, INC.
- Proposal award date
- 2019-09-16
- Contract end date
- 2020-08-31
- UEI
- HJVMCLNHEZ49
- Solicitation number
- PA18-575
- Topic code
- 300
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- SBIR Phase I:Sentiomed Injectable 14-day Biodegradable Glucose Sensor System
- Passive intracranial pressure sensor for hydrocephalus shunts and cranioplasty implants with ultrasound readout
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- A platform for T-cell receptor mimic antibody generation modeled using pHLA-A*11:01 KRAS G12D
- Combinatorial pipeline for discovery of anti-GPCR Nanobodies
- Development of a GBP-based glycosylation analysis system
- Extended-release injectable gel for multi-day treatment of postoperative pain
- eMOA: A Multi-Omic Service for Mechanism of Action Determination in Drug Screening
Research funding history
3 SBIR/STTR records share this UEI (2019–2022). Reported award amounts total $734,642. Reported amounts are not federal obligations.
Phases: Phase I
Agencies: Department of Health and Human Services, National Science Foundation